Entering text into the input field will update the search result below

Merck Has The Best Anti-Cancer Portfolio - Cramer's Lightning Round (7/6/18)

Jul. 09, 2018 7:14 AM ETCARA, YRD, BIDU, MRK, IBM, FDS, NLY, SGH, HPQ, PPG4 Comments


  • Cara Therapeutics is a good buy.
  • Stay away from Annaly Capital Management.
  • Accounting irregularities equal to sell.

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, July 6.

Bullish Calls

Cara Therapeutics (CARA): The stock is back to $20, and Cramer had recommended it at $17-18. It's a good buy here.

Merck & Co. (MRK): It has the best anti-cancer portfolio, and the company is not promotional. The stock yields 3%, and Cramer likes it.

IBM Corp. (IBM): Buy half now and half when it goes lower. The 4.4% yield is good, and Cramer expects the next earnings quarter to be okay.

FactSet Research Systems (FDS): "You’ve got smart money because I like that stock. I wish more people liked it. I’d put that in the fintech category. Boy, do people love fintech."

Bearish Calls

Yirendai (YRD): Cramer does not want to recommend Chinese stocks other than Alibaba (BABA) and Baidu (BIDU).

Annaly Capital Management (NLY): It has a big yield, but the company is opaque. Cramer does not recommend it.

SMART Global Holdings (SGH): Cramer thinks HP, Inc. (HPQ) is a much better buy.

PPG Industries (PPG): Out of discipline, Cramer does not buy stocks of companies with accounting irregularities.


Jim Cramer's Action Alerts PLUS: Check out Cramer's multi-million dollar charitable trust portfolio and uncover the stocks he thinks could be HUGE winners. Start your FREE 14-day trial now!

Get Cramer's Picks by email - it's free and takes only a few seconds to sign up

This article was written by

Mohit is the former Managing Editor for the Breaking News (India team) at Seeking Alpha. Currently working with Benzinga, he was with Seeking Alpha from January 2010 until August 2020. Before joining Seeking Alpha in January 2010, he worked with a start-up equity research firm in the capacity of a Team Leader tracking US company events and results.Born in the U.A.E, he spent most of my growing up years in Dubai. Currently, he resides in Mumbai, India.

Recommended For You

Comments (4)

Cramer hit the wall.
biochemist profile picture
What exactly is Cramer basing his MRK "has the best anti-cancer portfolio" on? Does he do any research on anything. Has he heard of companies like BMY, Roche, NVS, AZN, or JNJ? I like MRK and I think that Keytruda is a game-changing, and life-changing, new cancer therapeutic, but as far as I can see that is the totality of the Merck anti-cancer portfolio at present. If you want to include the joint ventures with AZN (olaparib) and Eisai (lenvatinib) it is early days for those anti-cancer therapies.
dislike cramer shrieked a buy recommendation when nly was more than 50% higher the guy is a pastiche
Michael Delaney profile picture
We get it Pauly. You have told us 14 times since May 1 that Cramer is a pastiche and you don't like him. How about offering up some actionable recommendations of your own on individual equities or investing in general?
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

Related Stocks

SymbolLast Price% Chg
Cara Therapeutics, Inc.
Yiren Digital Ltd.
Baidu, Inc.
Merck & Co., Inc.
International Business Machines Corporation

Related Analysis

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.